Alice Melão, MSc,  —

AmpliPhi Biosciences’ investigative therapy AB-PA01, in combination with antibiotics, shows significant potential to treat multi-drug resistant Pseudomonas aeruginosa infection in cystic fibrosis (CF), according to the case report of a CF patient with recurrent pneumonia and pulmonary exacerbations. These positive early results further support the development of the treatment against…

Treatment with inhaled mannitol is safe and can help to improve lung function in adult patients with cystic fibrosis (CF), a post hoc analysis of data from a concluded Phase 3 trial show. These results were discussed at the recent 41st European Cystic Fibrosis Society (ECFS) Conference in Belgrade,…

Results of the Phase 3 ARRIVAL study show that Kalydeco (ivacaftor) has the potential to modify the course of toddlers with cystic fibrosis. The trial’s most recent finding were discussed at the 41st European Cystic Fibrosis Society (ECFS) Conference taking place in Belgrade, Serbia, through June 9.

Exposure to tobacco smoke is a key contributor to worsening lung function in young children with cystic fibrosis (CF), researchers report in a study that highlights both the importance of routine checks of lung function in children, and smoking cessation programs as a part of CF care. The study’s results…

Preliminary clinical trial data of three investigational next-generation CFTR correctors, being developed by Vertex Pharmaceuticals, provides the first demonstration of their potential to improve the outcome of cystic fibrosis (CF) patients. Trial findings were presented today at the 41st European Cystic Fibrosis Society (ECFS) Conference, taking place…

Results of a Phase 2 trial showed that treatment with Spyryx’s investigative drug SPX-101 can improve lung function in patients with cystic fibrosis, regardless of their background genetic mutation causing the disease. The most recent trial data will be discussed at the 41st European Cystic Fibrosis Society…

Proteostasis Therapeutics will present an update on its cystic fibrosis (CF) clinical programs — which include an amplifier, a corrector, and a potentiator of the CFTR gene — at the upcoming 41st European Cystic Fibrosis Society (ECFS) Conference, June 6-9 in Belgrade, Serbia. In two presentations, the company will cover the most recent advances…

Antimicrobial peptides administered as tiny nanoparticles show promise in treating bacterial infections without risking making the bacteria more resistant to treatment — as can happen with antibiotics, an EU-supported study reports. Unlike antibiotics, antimicrobial peptides or AMPs are part of the innate immune system, naturally occurring molecules that work as…

Arrowhead Pharmaceuticals’ investigational cystic fibrosis treatment candidate ARO-ENaC can effectively target the epithelial sodium channel alpha subunit (αENaC) in the lungs of rats, preclinical studies show. Given that ENaC is a well-known mediator of common cystic fibrosis symptoms, such as airway dehydration and mucus accumulation, these…

An advisory committee composed by experts in the field of cystic fibrosis will help to guide the design of the global Phase 3 program testing PTI-428, the company developing the potential treatment, Proteostasis Therapeutics, announced. Its formation is a key step in ensuring that the program follows regulatory requirements, while retaining…